Apollomics vs Crescent Biopharma
APLM and CBIO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How APLM and CBIO compare
Crescent Biopharma scores higher on the StockData Score (10 against 0 for Apollomics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | APLM | CBIO |
|---|---|---|
| Size and price | ||
| Market cap | – | $534M |
| Share price | $17.30 | $14.37 |
| Change, 1 year | 13.0% | 8.5% |
| Change, 5 years | – | −92.4% |
| Beta (5Y) | 0.66 | 1.63 |
| Employees | 14 | 44 |
| StockData Score | ||
| Total score | 0 | 10 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 2 (better) |
| Health score | 0 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 35.6× |
| P/B | – | 1.9× |
| FCF yield | – | −15.4% |
| Growth | ||
| Revenue growth, 5Y average | – | 1.3% |
| Profitability | ||
| Operating margin | – | −1217% |
| Net margin | – | −728% |
| FCF margin | – | −550% |
| Return on equity | – | −55.8% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | 0.96 | 12.57 (better) |
| Altman Z-score | – | 10.62 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | – | 79.7% |
| Held by insiders | 76.0% | 38.6% |
| Insider net buying, 12 months | $8.3M | $29.1M (better) |
| Short interest, % of float | – | 18.3% |
Go deeper
- APLM stock overview
- APLM income statement
- APLM valuation and score
- CBIO stock overview
- CBIO income statement
- CBIO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.